Immunomodulatory drugs in autoimmune lymphoproliferative syndrome (ALPS)

Pediatric Blood and Cancer

Volumn 58, Issue 2, 2012, Pages 310-

  Tommasini, Alberto ^a   Valencic, Erica ^a   Piscianz, Elisa ^a   Rabusin, Marco ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOMODULATING AGENT; PENTOSTATIN; RAPAMYCIN; STEROID;

APHTHOUS STOMATITIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; DISEASE SEVERITY; DOUBLE NEGATIVE ALPHA BETA T LYMPHOCYTE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LETTER; LOW DRUG DOSE; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; DISEASES IN TWINS; HUMANS; MALE; PENTOSTATIN;

EID: 83455266402     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23205     Document Type: Letter

References (4)

1. Bajwa R, Savelli S, Gross T. Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 2011; DOI: 10.1002/pbc.23144.
2. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop. Blood 2010; 116: e35-e40.
3. Janic MD, Brasanac CD, Jankovic JS, et al. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 2009; 53: 1117-1119.
4. Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 2006; 108: 1965-1971.